# A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects

> **NCT05332834** · PHASE1 · COMPLETED · sponsor: **SinoMab BioScience Ltd** · enrollment: 77 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** SM17
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05332834
- **Lead sponsor:** SinoMab BioScience Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-14
- **Primary completion:** 2023-09-26
- **Final completion:** 2023-09-26
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05332834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05332834, "A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05332834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*